Premium
GROWTH HORMONE RESPONSES TO GRF 1–29 IN PATIENTS WITH PRIMARY HYPOTHYROIDISM BEFORE AND DURING REPLACEMENT THERAPY WITH THYROXINE
Author(s) -
VALCAVI R.,
JORDAN V.,
DIEGUEZ C.,
JOHN R.,
MANTCARDI E.,
PORTIOLI I.,
RODRIGUEZARNAO M. D.,
GOMEZPAN A.,
HALL R.,
SCANLON M. F.
Publication year - 1986
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1986.tb01666.x
Subject(s) - medicine , endocrinology , hormone replacement therapy (female to male) , hormone , growth hormone , testosterone (patch)
SUMMARY It is well known that hypothyroidism is frequently associated with impaired GH responses to different stimuli. In the present study we have evaluated GH responses to GH‐releasing factor (GRF) in patients with primary hypothyroidism before and during T4 replacement therapy. Fourteen patients (age range 26–60 years) underwent two GRF tests (1 μg/kg) before and during replacement therapy (150 μg/d). Administration of T4 increased peak GH responses to GRF in 9 patients and in the group as a whole (mean ± SEM, 17·0 ± 2·8 vs 32·6 ± 5·7 mU/l, P > 0·02). When the data are analysed by means of area under the curve (AUC), the GH response to GRF was increased by T4 in 10 patients and in the group as a whole (mean ± SEM, 51·7 ± 14·3 vs 101·5 ± 28·1, P > 0·02). These data indicate that thyroid hormone replacement therapy enhances the responsiveness of the somatotroph to GRF 1–29 in patients with primary hypothyroidism.